Akebia Therapeutics, Inc. (NASDAQ: AKBA) is a biopharmaceutical company based in Cambridge, Massachusetts. It focuses on developing and commercializing therapies for patients with kidney disease. As a player in the biopharmaceutical industry, Akebia faces competition from other companies developing similar treatments.
On November 10, 2025, Akebia is set to release its quarterly earnings. Wall Street estimates the earnings per share to be -$0.02, with projected revenue of approximately $58.2 million. The company will host a conference call at 8:00 a.m. EST to discuss these results and recent business highlights, as announced by Akebia.
Despite a negative price-to-earnings (P/E) ratio of -14.47, Akebia's price-to-sales ratio is about 2.62. This means investors are paying $2.62 for every dollar of the company's sales. The enterprise value to sales ratio is approximately 2.20, indicating the company's valuation relative to its revenue.
The enterprise value to operating cash flow ratio is significantly negative at around -186.85, highlighting challenges in generating cash flow from operations. The earnings yield is also negative at approximately -6.91%, further indicating financial difficulties for Akebia.
Akebia's debt-to-equity ratio is 1.83, suggesting a relatively high level of debt compared to its equity. However, the current ratio is approximately 1.98, indicating that the company has nearly twice as many current assets as current liabilities, suggesting a reasonable level of short-term financial health.
